Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | FAAH | O00519 | 5/20 | 0.44 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.40 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.40 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19359777 | 1.00 | CPB2 (0.45) | CPB2CA2FAAHZDHHC7LMNA | |
| SCHEMBL6900295 | 1.00 | CPB2 (0.45) | CPB2CA2FAAHZDHHC7LMNA | |
| SCHEMBL19359871 | 0.85 | HDAC1 (0.41) | CPB2CA2LMNACA1GRIK1 | |
| SCHEMBL6898426 | 0.85 | HDAC1 (0.41) | CPB2CA2LMNACA1GRIK1 | |
| SCHEMBL23879492 | 0.85 | CPB2 (0.58) | CPB2CA2ZDHHC7CA1GRIK1 | |
| SCHEMBL18531126 | 0.85 | CPB2 (0.58) | CPB2CA2ZDHHC7CA1GRIK1 | |
| SCHEMBL5580131 | 0.85 | CPB2 (0.58) | CPB2CA2ZDHHC7CA1GRIK1 | |
| SCHEMBL19148651 | 0.85 | CPB2 (0.58) | CPB2CA2ZDHHC7CA1GRIK1 | |
| SCHEMBL571313 | 0.85 | CPB2 (0.58) | CPB2CA2ZDHHC7CA1GRIK1 | |
| SCHEMBL25341592 | 0.85 | CPB2 (0.58) | CPB2CA2ZDHHC7CA1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2022-12-06 | — | — | US | disclosed |
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2020-12-31 | — | — | US | disclosed |
| US-10723728-B2 | Prodrugs of Nh-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-07-28 | — | — | US | disclosed |
| US-10351529-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-07-16 | — | — | US | disclosed |
| US-20190084937-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-03-21 | — | — | US | disclosed |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2018-08-07 | — | — | US | disclosed |
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2018-06-14 | — | — | US | disclosed |
| US-20170267639-A1 | Process for Synthesizing Oxidized Lactam Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-09-21 | — | — | US | disclosed |
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| US-9650341-B2 | Process for synthesizing oxidized lactam compounds | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-05-16 | — | — | US | disclosed |
| US-20120015866-A1 | Prodrugs of Heteraromatic Compounds | ALKERMES, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-20110275803-A1 | PROCESS FOR SYNTHESIZING OXIDIZED LACTAM COMPOUNDS | ALKERMES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011084850-A1 | PRODRUGS FOR THE TREATMENT OF SCHIZOPHRENIA AND BIPOLAR DISEASE | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084851-A1 | ASENAPINE PRODURUGS | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. | 2011-01-20 | — | — | US | disclosed |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. | 2011-01-06 | — | — | US | disclosed |
| WO-2010151711-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | ALKERMES, INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267639-A1 | Process for Synthesizing Oxidized Lactam Compounds | COASY, DHPS, OXA1L | CPB2 1659/4885CA2 3942/4885FAAH 3072/4885 |
| US-20200407320-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | CPB2 3347/4885CA2 4436/4885FAAH 565/4885 |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | SLC1A5, IDH1, ASS1 | CPB2 3709/4885CA2 258/4885FAAH 1017/4885 |
| US-20180162816-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | CPB2 3347/4885CA2 4436/4885FAAH 565/4885 |
| US-20190084937-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | CPB2 3347/4885CA2 4436/4885FAAH 565/4885 |
| US-10351529-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | CPB2 3347/4885CA2 4436/4885FAAH 565/4885 |
| US-10040787-B2 | Prodrugs of NH-acidic compounds | SI, NAAA, NIT2 | CPB2 1201/4885CA2 205/4885FAAH 203/4885 |
| US-20110166194-A1 | Asenapine Prodrugs | GRIN1, SCN1B, GRIN2B | CPB2 4576/4885CA2 4238/4885FAAH 193/4885 |
| US-20110275803-A1 | PROCESS FOR SYNTHESIZING OXIDIZED LACTAM COMPOUNDS | COASY, DHPS, OXA1L | CPB2 1659/4885CA2 3942/4885FAAH 3072/4885 |
| US-20110166128-A1 | Diaryldiazepine Prodrugs for the Treatment of Neurological and Psychological Disorders | HTR5A, HTR2C, HTR2B | CPB2 3485/4885CA2 3676/4885FAAH 164/4885 |
| US-20120015866-A1 | Prodrugs of Heteraromatic Compounds | CYP2D6, CYP2B6, CYP3A4 | CPB2 1813/4885CA2 2668/4885FAAH 735/4885 |
| US-20110003828-A1 | PRODRUGS OF NH-ACIDIC COMPOUNDS | SI, NAAA, NIT2 | CPB2 1201/4885CA2 205/4885FAAH 203/4885 |
| US-10723728-B2 | Prodrugs of Nh-acidic compounds | SI, NAAA, NIT2 | CPB2 1201/4885CA2 205/4885FAAH 203/4885 |
| US-11518745-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | CPB2 3347/4885CA2 4436/4885FAAH 565/4885 |
| US-20110015156-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | CPB2 3347/4885CA2 4436/4885FAAH 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.